Metrion Biosciences Ltd.. (9/8/20). "Press Release: Metrion Biosciences Strengthens Global Business Development Team". Cambridge.

	Region	United States (USA)
	Organisation	Metrion Biosciences Ltd.
	Product	drug discovery services
	Product 2	preclinical research
	Person	Southan, Andrew (Metrion Biosciences 201904– promoted to CEO joined 201610 before CeNeS + Ionix + BioFocus)

> Two appointments in USA and Europe increase representation across key regions

> Partnership established with On Target Drug Discovery Service and Supply, Ltd. to represent Metrion in Japan

Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, today announced it has significantly enhanced its global business development capabilities, with additional resources now committed to support key regions in the USA, Europe and Japan.

Anca Haralambie has been appointed as Business Development Executive, representing Metrion in the UK and across Europe. Anca has broad experience of supporting clients in the global drug discovery sector, with particular expertise in translational research and induced pluripotent stem cells (iPSC).

Mari Kennedy will be supporting Metrion in the mid-west and east coast USA. Mari is an experienced ion channel sales and marketing executive, and joins Metrion’s west coast representatives Candidate Biopharma Advisors, to support the Company’s USA client base.

In Japan, Metrion will be represented by On Target Drug Discovery Service and Supply, Ltd. (On Target), based in Tokyo. On Target specialises in the sales and marketing of pre-clinical drug discovery services and related products from provider partners located outside of Japan, and will be working to support and expand upon Metrion’s customer base in the region.

Dr Andrew Southan, CEO, Metrion Biosciences, said: “Metrion has adopted an ambitious business plan to capitalise upon our unique position in the ion channel contract research arena. By strengthening our business development team we aim to raise further awareness of our capabilities in key territories and expand our portfolio of clients seeking to outsource high quality ion channel drug discovery and safety profiling services.”

Dr. Keiichi Yokoyama, founder and Managing Director, On Target,said:"On Target is pleased to support the expansion of Metrion's leading services portfolio within the Japan drug discovery community. We are fully committed to helping Metrion achieve its business goals in our territory by leveraging the Company’s scientific expertise with On-Target's market-specific experience and technical sales capability.”

ENDS

Notes to Editors

Dr Andrew Southan, CEO, Metrion Biosciences
Anca Haralambie, Business Development Executive, Metrion Biosciences
Mari Kennedy, mid-west and east coast USArepresentative

For further informationand high-resolution imagesplease contact:

For Metrion Biosciences
Katie Odgaard
Zyme Communications
E-mail: katie.odgaard@zymecommunications.com
Tel: +44 (0)7787 502 947

About Metrion Biosciences
www.metrionbiosciences.com

Metrion Biosciences is a specialist ion-channel contract research organisation and drug discovery business. The Company provides customers with access to a range of high quality ion channel assays on a fee-for-service or collaboration basis. Metrion Biosciences’ ion channel expertise includes an industry leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimisation. Metrion Biosciences is able to provide tailored assay formats, data analysis and reporting solutions, effective project management and quality assured data packages.

Twitter: @Metrion_Biosci
LinkedIn: https://www.linkedin.com/company/metrion-biosciences/

About On TargetDrug Discovery Service and Supply, Ltd.
http://ontarget-ddss.co.jp/

On Target Drug Discovery Service and Supply, Ltd. is a Japanese company specializing in the sales and marketing of pre-clinical drug discovery services and related products from provider partners located outside of Japan. For our provider partners, we offer single-point-of-contact access to Japan's entire pharma and biotech research community. As local representative, we greatly facilitate both the willingness and the ability of Japanese researchers to access our provider's services. Founded in 2011 with many years of prior experience, On Target's success is built on our technical sales expertise, market knowledge, and dedication to strong communications with our provider partners and local clients.

Record changed: 2023-06-05